Title : Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.

Pub. Date : 2014 Mar-Apr

PMID : 24492289






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners. Lapatinib erb-b2 receptor tyrosine kinase 3 Homo sapiens
2 In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners. Lapatinib erb-b2 receptor tyrosine kinase 3 Homo sapiens
3 In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners. Lapatinib erb-b2 receptor tyrosine kinase 3 Homo sapiens
4 In the first approach, we generated a bispecific anti-HER2/HER3 antibody that, in the presence of lapatinib, is designed to sequester HER3 into inactive HER2-HER3 dimers that restrain HER3 interactions with other possible dimerization partners. Lapatinib erb-b2 receptor tyrosine kinase 3 Homo sapiens